Weifang Shengtai Medicine Co., Ltd. Delivers Premium Dextrose Monohydrate for Global Pharmaceutical & Food Industries

Weifang Shengtai Medicine Co., Ltd., a core subsidiary of Shengtai Group and a national high-tech enterprise, is a world-leading manufacturer and supplier of high-grade dextrose monohydrate, with a long-standing focus on R&D, production and sales of pharmaceutical and food raw materials.

As a key player in China’s glucose industry, the company boasts an annual output of 300,000 tons of glucose-series products, among which dextrose monohydrate covers injection-grade, pharmaceutical-grade and food-grade specifications. Its injection-grade dextrose monohydrate production scale ranks first in China, holding a domestic market share of over 70%, and is one of the few licensed manufacturers of injection-grade glucose in China.

Product Highlights & Applications

Injection-grade Dextrose Monohydrate: Produced via advanced double-enzyme technology, refined through decolorization, ion exchange, crystallization and drying. It features ultra-high purity, low impurity and stable quality, widely used in intravenous infusion and critical medical preparations.

Food-grade Dextrose Monohydrate: A white crystalline powder with mild sweetness, compliant with national food safety standards. It serves as a key sweetener, nutritional supplement and fermentation substrate in food, beverage, confectionery and bio-fermentation industries.

Quality & Global Recognition

The company has passed a full set of international certifications, including GMP, ISO9001, ISO22000, FSSC 22000, Halal, Kosher and Non-GMO IP, ensuring product safety and traceability. Its dextrose monohydrate is sold to more than 70 countries and regions across Asia, Europe, North America and Africa, earning high trust from global pharmaceutical factories, food producers and brand customers.

Strategic Development

Adhering to green and intelligent manufacturing, Weifang Shengtai is accelerating capacity upgrading and product structure optimization. With a total investment of 9 billion yuan in high-end projects, the company will further expand its high-quality dextrose monohydrate supply capacity, strengthen its global leadership, and provide safer, more stable and professional sugar raw material solutions for the world’s pharmaceutical and food industries.